Paradoxical Growth Hormone Response following Thyroid-Stimulating Hormone Administration in the Polycystic Ovary Syndrome

Anapliotou, Margarita; Syrigos, Kostas; Panayiotakopoulos, George; Kalos, A; Batrinos, Menelaos L.

doi:10.1159/000181100

Cited by 7 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…110 However, a height ened prolactin response to TRH administration in PCO patients relative to controls is not observed. 111 Although estrogen may directly stimulate the pitu itary lactotrope to enhance prolactin secretion, it may also do so by acting indirectly by sensitizing the lactotrope to GnRH. Increased release of LH after GnRH administration occurs in both healthy and PCO women given exogenous estrogen, 112,113 but not consistently since in some women LH levels fall 97 or remain the same.…”

Section: Estrogenmentioning

confidence: 99%

Hyperprolactinemia and Polycystic Ovarian Syndrome

Zacur¹,

Foster²

1992

Semin Reprod Med

View full text Add to dashboard Cite

Section: Estrogenmentioning

confidence: 99%

Hyperprolactinemia and Polycystic Ovarian Syndrome

Zacur¹,

Foster²

1992

Semin Reprod Med

View full text Add to dashboard Cite

“…That 24-hour GH values are higher only in non-obese PCO patients could also explain why published data on GH concentrations in PCO have shown such variable results [21][22][23]. Thus Lanzone et al [22] found no differ ence in GH and IGF-I values in PCO compared to that in healthy women, whilst Kazer et al [23] reported lower GH concentrations despite normal IGF-I values.…”

Section: Discussionmentioning

confidence: 98%

Twenty-Four-Hour Serum Growth Hormone, Insulin, C-Peptide and Blood Glucose Profiles and Serum Insulin-Like Growth Factor-l Concentrations in Women with Polycystic Ovaries

et al. 1992

View full text Add to dashboard Cite

Raised insulin levels are now recognized as a characteristic feature of women with polycystic ovaries (PCO), and hyperinsulinism has been shown to stimulate androgen production in such women. We have, however, recently shown that hyperinsulinaemia is present only in the obese subjects with PCO in whom insulin concentrations correlate with those of luteinizing hormone. We therefore studied 24-hour blood profiles of growth hormone (GH) and insulinlike growth factor-I (IGF-I) in obese and non-obese women with PCO, for comparison with their levels of insulin, C-peptide and other hormones, such as androgens which are known to be disturbed in PCO. Mean 24-hour GH levels were higher overall in PCO than in control subjects, although the difference was not significant. When, however, a separate analysis was made in obese as compared with non-obese PCO patients, GH concentrations were significantly higher in the non-obese group than in the obese (p = 0.0005). There was a significant negative correlation between body mass index and mean 24-hour GH concentrations (r = -0.641; p = 0.0006). IGF-I concentrations were however similar in the PCO group overall and in controls, as well as in the obese and non-obese PCO patients. The 24-hour blood glucose profile pattern was significantly different in PCO women from controls (p = 0.009), with absence of post-prandial peaks in blood glucose concentrations. These changes were most marked in the non-obese PCO group, who also had significantly lower blood glucose levels than either controls or obese PCO subjects. Significantly higher 24-hour C-peptide and insulin concentrations were found in the obese PCO group compared with controls and the non-obese PCO group. The absence of typical post-prandial increases in insulin and C-peptide concentrations was also evident in the non-obese PCO subjects. There was a significant negative correlation between the 24-hour C-peptide and mean 24-hour GH values (r = – 0.629; p = 0.0212) in the PCO group. Our finding of higher GH concentrations in non-obese PCO patients together with lower blood glucose and normal IGF-I concentrations could theoretically be explained in terms of altered IGF-binding protein concentration, which in turn would influence the biological potency of IGF-I and regulation of GH secretion. These findings would also support the concept that part of the disturbance in patients with PCO lies between that of insulin and IGF-I binding protein.

show abstract

GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome

Orio

Palomba

Colao

et al. 2003

J Endocrinol Invest

View full text Add to dashboard Cite

Few and unclear data are available in the literature about the relationship between impairment of GH/IGF-I axis and polycystic ovary syndrome (PCOS). This study was aimed to evaluate the basal GH and IGF- levels, and GH release after challenge test in obese and overweight women with PCOS. Thirty patients with PCOS and other 30 healthy women matched for age, body mass index (BMI) and waist-hip ratio (WHR) were studied. Serum follicle-stimulating hormone (FSH), LH, PRL, E2, P, 17OH-progesterone (17OH-P), total T, delta4, DHEA-S, SHBG, GH and IGF-I levels were evaluated in each subject. A GHRH plus arginine challenge test was performed in all subjects. After provocative test, in PCOS and control women the GH levels were significantly (p<0.05) higher in comparison to basal values from 30 min to 120 min. At the same times, a significant (p<0.05) difference was observed between women with PCOS in comparison to healthy women. The mean peak value of GH resulted significantly (p<0.05) lower in PCOS women in comparison to healthy women. The total GH response (area under curve, AUC) to GHRH plus arginine test resulted significantly (p<0.05) lower in PCOS than in healthy women. These findings were statistically significant (p<0.05) also considering the distinction in obese and overweight women. The AUC for GH secretion was significantly lower (p<0.05) in obese in comparison to overweight subjects in the control group, whereas no significant difference was detected between obese and overweight women in the PCOS group. In conclusion, in PCOS women there is a BMI-independent alteration of the GH levels. Further investigations will be necessary to establish the real cause of these data.

show abstract

Paradoxical Growth Hormone Response following Thyroid-Stimulating Hormone Administration in the Polycystic Ovary Syndrome

Cited by 7 publications

References 26 publications

Hyperprolactinemia and Polycystic Ovarian Syndrome

Hyperprolactinemia and Polycystic Ovarian Syndrome

Twenty-Four-Hour Serum Growth Hormone, Insulin, C-Peptide and Blood Glucose Profiles and Serum Insulin-Like Growth Factor-l Concentrations in Women with Polycystic Ovaries

GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome

Contact Info

Product

Resources

About